Pre-exposure prophylaxis program in the Community of Madrid: Two years of experience.
Chemsex
Human immunodeficiency virus
Infecciones de transmisión sexual
Pre-exposure prophylaxis
Profilaxis pre-exposición
Sexually transmitted infections
Virus de la inmunodeficiencia humana
Journal
Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
10
12
2023
revised:
29
03
2024
accepted:
30
03
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
Pre-exposure prophylaxis (PrEP) against the human immunodeficiency virus (HIV) is an effective and safe preventive measure. However, it has not reached all target users who could benefit from it. The study aimed to understand the sociodemographic, clinical and behavioral baseline characteristics of PrEP users. As a secondary objective, the use of concomitant medication and drug consumption were described. Observational, retrospective and descriptive study of the sociodemographic, clinical and behavioral characteristics of the users who were included in the PrEP program of the Community of Madrid during the first two years of experience. Two thousand two hundred fifty-six PrEP users were included, 99.0% men, with a mean age of 36.9 years (SD 8.68). 33.1% presented a sexually transmitted infection (STI) on the first visit, highlighting chlamydiasis and rectal gonococci. 70.4% reported using drugs associated with sex, and 42.4% participated in chemsex sessions in the last 3 months. A high percentage of users with concomitant medication was observed (37.6%), highlighting drugs related to mental health and alopecia. A multidisciplinary approach is required to cover all the needs of PrEP users, including mental health evaluation measures and addiction treatment with the clinical approach.
Identifiants
pubmed: 38897909
pii: S2529-993X(24)00147-3
doi: 10.1016/j.eimce.2024.06.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.